

1 **Retrospective analysis of the clinical characteristics of *Candida auris* infection cases over a**
2 **10-year period¹**

3 Shan Hu,^{a,b,c,#} Yuehua Wang,^{a,d,#} Weiwei Jiang,^{e,#} Feilong Zhu,^f Yongqiang Quan,^g Guoming
4 Zhang,^h Feng Gu,^b Bing Gu,^{c,i,*} Ying Yang^{a,*}

5 ^a Department of Biotechnology, Beijing Institute of Radiation Medicine, Beijing, People's
6 Republic of China; Beijing Key Laboratory of New Molecular Diagnosis Technologies for
7 Infectious Diseases, Beijing, People's Republic of China.

8 ^b Department of Laboratory Medicine, Xuzhou Tumor Hospital, Xuzhou, People's Republic of
9 China.

10 ^c Medical Technology School of Xuzhou Medical University, Xuzhou Key Laboratory of
11 Laboratory Diagnostics, Xuzhou, People's Republic of China.

12 ^d Department of Life Science, Hebei University, Baoding, People's Republic of China.

13 ^e Shanghai Key Laboratory of Molecular Medical Mycology, Shanghai Institute of Mycology,
14 Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, People's
15 Republic of China.

16 ^f The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University, Xuzhou
17 Rehabilitation Hospital, Xuzhou, People's Republic of China.

18 ^g Department of Nephrology, Affiliated Huaihai Hospital of Xuzhou Medical University, Xuzhou ,

¹ Correspondence:

Ying Yang, Department of Biotechnology, Beijing Institute of Radiation Medicine, Beijing, PR China; Beijing Key Laboratory of New Molecular Diagnosis Technologies for Infectious Diseases, Beijing, 100850, PR China.

Email: y_ying_77@163.com

Bing Gu, Department of Laboratory Medicine, Affiliated Hospital of Xuzhou Medical University, Xuzhou, PR China.

E-mail: binggu2015@xzhmu.edu.cn

Author contributions:

Y.Y. and B.G. conceived and designed the study. S.H., Y.W., W.J. and Y.Q. collated and collected data, F.Z., G.Z. and F.G. did the statistical analysis. S.H., Y.W., W.J. and Y.Y. drafted the manuscript. All authors played a significant role in data collection and analysis.

#S.H., Y.W. and W.J. contributed equally to this work.

19 People's Republic of China.

20 ^h Department of Laboratory Medicine, Shuyang People's Hospital, The affiliated Shuyang
21 Hospital of Xuzhou Medical University, Shuyang, People's Republic of China.

22 ⁱ Department of Laboratory Medicine, The Affiliated Hospital of Xuzhou Medical University,
23 Xuzhou, People's Republic of China.

24

25 Running Head: Characteristics of *C. auris* infections over 10 years.

26 Word count: The word count of the abstract is 249 and the text is 4041.

27

28 **Abstract**

29 *Candida auris* is an emerging multidrug-resistant fungus with a high mortality rate. The first
30 case of *Candida auris* infection was reported in 2009 and since then infections have been reported
31 in nearly 40 countries. The fungus now represents a major global public health threat. We analyzed
32 cases from the emergence of *Candida auris* infections up until the end of 2019.

33 PubMed and Web of Science databases were searched for all papers related to *Candida auris*
34 infections up until 31 December 2019. We organized these data into the following categories: date
35 of publication, patient age and gender, underlying diseases, risk factors for infection, patient
36 mortality information, drug sensitivity information of *Candida auris* isolates, and genetic
37 classification. The χ^2 test was used to screen for factors that may affect patient mortality before
38 logistic regression analysis was used to further assess the suspected influencing factors to
39 determine if they represent independent factors for patient mortality.

40 Information pertaining to 542 patients was included. There were more male patients than
41 female patients and the mortality rate was higher in males than females. A high proportion of
42 patients were premature babies and elderly people. The proportions of patients with underlying

43 diseases such as diabetes, kidney disease, and ear disease were also high. 65% of patients had a
44 history in ICU and 60% were given broad-spectrum antibiotics. Logistic regression analysis
45 revealed that kidney disease ($P<0.05$) and tumors ($P<0.05$) are independent factors that affect
46 mortality in *Candida auris*-infected patients. Patients infected with echinocandin-resistant
47 *Candida auris* ultimately die.

48 **Keywords:** *Candida auris*; Infection characteristics; Risk factors; Drug-resistant; Influencing
49 factor for mortality.

50

51

52 **Introduction**

53 Since 2009 when the first *Candida auris* infection case was reported in Japan (1) until 31
54 December 2019, *Candida auris* infections have been reported in nearly 40 countries around the
55 world (2). In April 2019, the New York Times reported a multidrug-resistant fungal infection
56 outbreak in many parts of the United States. The causative agent of this outbreak was *Candida*
57 *auris*; however, the aforementioned article referred to the infections as “mysterious infections” and
58 deemed the outbreak an “urgent threat”. Nearly 50% of infected individuals died within 90 days
59 and the outbreak subsequently attracted widespread global attention (3). Because of the associated
60 high mortality rates, *Candida auris* can now be considered a major global public health threat (4).

61 Before 2009, *Candida auris* was thought to be a rarely observed microorganism and as a
62 result it is now deemed an emerging human pathogen (5). *Candida auris* can colonize different
63 sites, such as the skin, axilla, nose, and groin and is transmitted by contact or through feces. In
64 addition, the pathogen can survive on inanimate object surfaces for more than 7 days (6, 7).
65 Therefore, hospital beds, sphygmometers, thermometers, and other reusable equipment are
66 potential infection sources for inpatients. This has resulted in relatively high rates of *Candida auris*
67 transmission in inpatients, particularly in ICU rooms (8). This latter phenomenon has led to a
68 vicious cycle of acquisition, transmission, and infection (9, 10). It is hard to eradicate *Candida*
69 *auris* once it has colonized a patient and colonization of patients can last for 3 or more continuous
70 months (11). Even though many countries have implemented infection prevention and control
71 (IPC) strategies, *Candida auris* transmission is still a problem that warrants attention.

72 The appearance of multidrug resistance (MDR) in *Candida auris* is another problem that has
73 attracted global attention in recent years (12). The sensitivity of many *Candida auris* isolates
74 towards fluconazole has decreased and associated strains have developed varying degrees of

75 resistance to other antifungal drugs (13). Public health guidelines recommend that echinocandins
76 (micafungin, caspofungin, anidulafungin) should be used as first-line treatments for *Candida auris*
77 infections (14, 15). However, the continuous evolution of *Candida auris* has resulted in
78 echinocandin resistance. Indeed, the minimum inhibitory concentrations (MIC) of some isolates
79 towards azoles, amphotericin B, and echinocandin have even increased (13, 16). Therefore, close
80 attention is required in relation to the evolution of *Candida auris*.

81 Traditional identification techniques cannot be used to identify *Candida auris*. Therefore, the
82 prevalence of *Candida auris* infections in the global population remains unknown. Furthermore,
83 *Candida auris* has resulted in an “invisible pandemic” due to its broad nosocomial infection range
84 (11). Thus, it is extremely important to comprehensively understand the characteristics of *Candida*
85 *auris* itself along with the patients that the fungus infects. With this in mind, we collected papers
86 from the last 10 years since the first report of *Candida auris* and extracted information pertaining
87 to the patients’ age and gender, underlying disease, possible risk factors that may induce infection,
88 genetic phenotype classification of *Candida auris* isolates, drug susceptibility information, and
89 drug resistance loci. We compiled this information and conducted a statistical analysis to identify
90 new infection-related characteristics. The mortality rate of *Candida auris* infection patients is an
91 important factor that threatens global public health (4). Therefore, this study employed a
92 conservative regression model to determine the effects of several factors on patient mortality. We
93 believe that this analysis and summary of the relevant data will result in a greater public
94 understanding of *Candida auris* infections, thereby enabling scientists to focus greater attention on
95 the evolution of multidrug resistance in *Candida auris*.

96

97 **Methods**

98 **Case inclusion**

99 Authoritative literature search databases (PubMed and Web of Science) were used to conduct
100 the literature search using the following search criteria: 1. Titles or abstracts containing the
101 keyword *Candida auris*; 2. Time range with unlimited start date and an end date of 31 December
102 2019. Three hundred and sixty-five papers were identified through the literature search.
103 Experimental study papers were excluded while case reports were selected for the analysis. A total
104 of 76 papers on *Candida auris* case reports were included; these reports involved nearly 4000
105 patients (See Appendix 1).

106 The papers were organized and analyzed after case screening. Firstly, repeated cases were
107 excluded: Suspected repetitive cases from the same year and country that were reported in some
108 papers were excluded based on isolate number, detection time, and detection unit. Cases with
109 incomplete information were excluded. As this study predominantly analyzed case characteristics,
110 cases with incomplete information were excluded. The specific data of 542 detailed cases were
111 included in the statistical analysis conducted as a part of this study.

112 **Data entry**

113 The following information required for analysis was inputted:

114 1. Paper information (combined with data from the US Centers for Disease Control)²:

115 (1) Country of publication; (2) Year of publication;

116 2. Patient information;

117 (1) Basic information of patients: including gender, age, and whether patient is a
118 premature infant.

119 (2) Underlying diseases of the patient: including common systemic diseases such as
120 hypertension, diabetes, and hyperlipidemia; comorbid infections such as AIDS, syphilis, and
121 cytomegalovirus (CMV) infection; solid organ diseases were classified based on the site, such
122 as kidney disease, lung disease, and brain disease.

123 (3) Risk factors that may induce *Candida auris* infection: including use of central venous
124 catheter, use of broad-spectrum antibiotics, parenteral nutrition, and intensive care unit
125 admission.

126 (4) Patient mortality status: whether patient died and cause of death.

127 3. Isolate information:

128 (1) Drug sensitivity information: minimum inhibitory concentration (MIC) of common
129 antifungal drugs and drug resistance loci;

130 (2) Genetic classification: Different isolates were classified based on genetic polymorphisms
131 into: South Asia (clade I), East Asia (clade II), South Africa (clade III), and South America (clade
132 IV) (17).

133 In order to ensure the accuracy of analysis, each inputted dataset required review by at least 3
134 members of the team before it was accepted. In this study, the Beijing Key Laboratory for
135 Molecular Diagnostics of Infectious Diseases was deemed the leading site and it established a
136 research team consisting of one clinician, two laboratory physicians, one medical mycology
137 researcher, and one pharmacology researcher.

138 **Data organization and statistical analysis**

139 In this study, underlying diseases predominantly included 3 categories encompassing

140 systemic diseases, comorbid infection, and organ diseases; these were further divided into 50
141 subcategories. Suspected patients were not included in the statistics.

142 In order to avoid the repetition of statistical analyses pertaining to drug sensitivity data, the
143 most recent data for an isolate was used when the same method was employed to analyze more
144 than one drug sensitivity experiment. Interestingly, the MIC values for the most recent results
145 generated from drug sensitivity experiments in all papers were the highest. When the broth method
146 and standard commercial reagents were both used for drug sensitivity experiments for the same
147 isolate, the drug sensitivity results obtained using standard commercial reagents were chosen for
148 analysis because operator error tended to occur when the broth method was used. When different
149 standard commercial drug sensitivity test systems (VITEK®2 and Sensititre® YeastOne® were
150 used in this study) were used for the same isolate, the test results from the VITEK®2 system were
151 selected as the inter-laboratory consistency of VITEK®2 was higher than that for Sensititre®
152 YeastOne® (18).

153 The mortality rate of *Candida auris* infection is an important factor that threatens global
154 public health. Hence, in this study we felt that it was important to screen for factors that affected
155 patient mortality. The χ^2 test was used to screen for single factors that might affect mortality. A
156 p-value < 0.05 indicated that the suspected factor was significant. Significant suspected factors
157 were included in multivariate analysis. If the number of significant suspected factors obtained
158 during univariate analysis was less, the criteria for inclusion in the multivariate analysis were
159 broadened to P < 0.1 (19, 20). For the multivariate analysis, we constructed a binary logistic
160 regression model (21) to screen for independent influencing factors that affect the outcome (patient
161 mortality). The outcome marker (death) was the dependent variable and all potential factors that
162 affect patient mortality were independent variables. Potential factors that affect patient mortality


163 included: gender, age, underlying disease, and drug resistance of the isolate. For influencing
164 factors obtained by univariate analysis, only those with a partial regression coefficient of $P < 0.05$
165 in regression model analysis could significantly affect the outcome marker (patient mortality)
166 (21).

167

168 Results

169 Initial infection reports in different countries

170 Since 2009 when *Candida auris* was first isolated from an auditory canal of a patient in Japan,
171 infections have also been reported in South Korea (22), India (23), South Africa (24), and Kuwait
172 (25). After 2016, the number of countries with first reports of *Candida auris* infections started to
173 increase. In 2018, 14 countries reported *Candida auris* infections for the first time, this was the
174 highest number of countries reporting infection for the first time in 10 years (shown in Figure 1).



175

176 Figure 1: Date of first report and genetic classification for various countries (South Asia (clade I),
177 East Asia (clade II), South Africa (clade III), and South America (clade IV))

178

179 Genetic classification of isolates detected in various countries

180 The isolates detected by various countries were classified by whole genome sequencing data
181 into South Asia strains (clade I), East Asia strains (clade II), South Africa strains (clade III), and
182 South America strains (clade IV). The South Asia strains (clade I) were the most prevalent (17
183 countries), followed by the South Africa strains (clade III) which were observed in 8 countries.
184 Only 4 and 3 countries reported the presence of the East Asia strains (clade II) and the South
185 America strains (IV), respectively. Both South Asia and South Africa strains simultaneously
186 occurred in China, Germany, UK, and Saudi Arabia. All 4 clades appeared in the US, a
187 phenomenon that may be due to large population movements. In addition, an isolate identified in
188 Iran in 2019 may represent a potential clade V strain (shown in Figure 1) (17).

189 **Patient gender and age distribution**

190 For the included patients, gender was mentioned for 509 patients, of which 296 (58%) were
191 male and 213 (42%) were females. The male to female ratio was around 3:2 and infection resulted
192 in significant gender differences. This is shown in Figure 2a.

193 The World Health Organization age group classification criteria (20) were used to divide
194 patients into children (0–18 years), adolescents (19–44 years), middle-aged (45–59 years), and
195 elderly (≥ 60 years). Figure 2b shows the age distribution of 195 cases in which age was mentioned.
196 Most patients, approximately half of the population ($n=93$, 48%), were elderly. Fifteen of the
197 patients were infants less than 1 month old; 10 of the 15 (2/3 of the infant population) patients were
198 premature infants. Therefore, the possibility of *Candida auris* infection should be considered
199 when premature infants present with infection symptoms due to unknown causes.



200
201 Figure 2: Gender and age distribution of patients. a). Gender distribution: males (58%) and
202 females (42%). b). Age distribution: 0–18 years (14%), 19–44 years (13%), 45–60 years (26%),
203 ≥60 years (48%).

204

205 **Underlying disease and infected population**

206 Underlying diseases were mentioned for 418 patients, of which the highest proportion of
207 underlying diseases were diabetes, kidney disease (some have diabetic nephropathy), and ear
208 disease. In addition, 12 patients were co-infected with HIV (as shown in Table 1).

209 Table 1. Underlying diseases in *Candida auris*-infected patients

Underlying disease	Number of people with disease	Proportion of patients
Diabetes	88	21%
Kidney disease	86	21%
Ear disease	74	18%
Trauma	63	15%
Lung disease	46	11%

Tumor	42	10%
Brain disease	41	10%
Sepsis	39	9%
Hypertension	37	9%
Heart disease	24	6%
Intestinal disease	18	4%
Liver disease	15	4%
Hematologic disease	12	3%
HIV	12	3%
Vasculopathy	10	2%
Thyroid disorder	7	2%
Diarrhea	7	2%
Pancreatic disease	4	1%
Bone marrow disease	4	1%
Urinary tract disease	4	1%
Pressure ulcer	4	1%
Nasopharyngeal disease	3	1%
Psychiatric disorder	3	1%
Other diseases	33	8%

210 Note: Other diseases are underlying disease categories with proportion of patients <0.5%.

211

212 **Risk factors that may lead to infection and infected population**

213 Risk factors for infection were mentioned for 389 patients (Table 2). Greater than 60% of
214 patients had an ICU treatment history and a history of broad-spectrum antibiotic use. These factors
215 represent high risk factors for *Candida auris* infection and are consistent with the risk factors
216 espoused by global experts in relation to *Candida auris* emergence and transmission (19,20).

217 Table 2: Risk factors involved in contact with *Candida auris* infected patients

Risk factor	Number of patients	Proportion of patients
ICU	254	65%
Broad-spectrum antibiotic treatment	232	60%
Central venous catheter	182	47%
Urinary catheter	141	36%
Underwent surgery in last 30 days	115	30%
Treatment with antifungal drugs in last 30 days before testing positive	104	27%
Mechanical ventilation	60	15%
Parenteral nutrition	40	10%
Steroid treatment	35	9%
Immunosuppressant	28	7%
Neutropenia	11	3%
Blood transfusion	4	1%

218


219

220 **Drug-resistant *Candida auris* strains**

221 Large differences in efficacy were observed for antifungal drugs in relation to the treatment of
222 infection of different *Candida auris* isolates (13). The US Centers for Disease Control (CDC)
223 defined conservative break points to determine whether *Candida auris* is resistant to antifungals:
224 fluconazole (FLC): 32 µg/mL, amphotericin B (AMB): 2 µg/mL, micafungin (MFG): 4 µg/mL,
225 and caspofungin (CAS): 2 µg/mL (2). In another study by the US CDC, break points for
226 voriconazole (VRC): 2 µg/mL, anidulafungin (AFG): 4 µg/mL, and flucytosine (5-FC):128
227 µg/mL were established. A MIC < cutoff was defined as sensitive while a MIC ≥ cutoff was
228 defined as resistant (25). Among the isolates that were included in the analysis, drug resistance
229 information was available for 323 isolates; the proportion of isolates exhibiting FLC resistance
230 was the highest (72%), while isolates exhibiting AMB (27%) and VRC (25%) resistance were the
231 second and third most prevalent, respectively (Figure 3a). Among the VRC-resistant isolates, 18
232 Venezuelan isolates reported by Calvo et al. (7) and 8 USA isolates reported by Park et al (27).
233 were completely resistant to VRC.

234 MIC information was accessible for 118 isolates in the literature and this information was
235 used to determine drug resistance (Figure 3b). Among these isolates, 17 isolates (14%) were
236 sensitive, 45 isolates (38%) were resistant to one antifungal, 36 isolates (31%) were resistant to
237 two antifungals, 19 isolates (16%) were resistant to three antifungals, and 1 isolates (1%) was
238 resistant to five antifungals. An analysis of these data revealed that there was no statistical
239 correlation between the degree of multidrug resistance in *Candida auris* and patient mortality
240 (Table 3). It should be noted that sensitive ones were isolated from 5 dead patients and the only
241 sensitive isolate was from only a surviving patient. Only one isolate was resistant to 5 drugs (FLC,
242 VRC, ITC, AMB, and CAS) and this isolate was obtained from a dead patient from Malaysia.
243 Currently, echinocandin is the only first-line drug for *Candida auris* infection (14,15). When

244 echinocandin resistance is present in the patient, the outcome is always death.



245
246 Figure 3: Drug resistance of *Candida auris*. a). Drug resistance status of *Candida auris* against 8
247 common antifungals. b). Drug resistance status of *Candida auris* isolates. MDR: multi-drug
248 resistance. S: sensitive, R1-R5: drug resistance status

250 Drug resistance loci

251 Among the isolates reported to date, the major drug resistance loci for azoles are ERG11,
252 CDR1, and MDR1 (27,28,29); the major drug resistance loci for AMB are ERG 2, 3, 5, 6, or 11
253 (30); and the major drug resistance locus for echinocandin is FKS11 (31,32). As part of a
254 mechanistic analysis of drug resistance towards 5FC, Rhodes et al (16). sequenced the entire
255 genome of 5FC-resistant *Candida auris* and found an amino acid substitution in F211I in the
256 FUR1 gene. However, further studies are required to determine whether this FUR1 mutation is the
257 cause of 5FC resistance in *Candida auris* (16).

258 Mortality rate

259 A total of 218 cases reported whether patients died or survived upon discharge. Among the
260 latter cases, 97 died and the mortality rate was 44%. Gender information was available for 88 dead
261 patients, of which 29 out of 53 males died and the mortality rate was 53%; 14 out of 35 females
262 died and the associated mortality rate was 40%; the mortality rate for males was slightly higher.
263 Major causes of death that were mentioned included sepsis, septic shock, and multiorgan failure.

264 **Influencing factor for mortality**

265 Among the patients included in the analyzed cases, the underlying disease of 100 patients
266 corresponded to pre-discharge mortality and could be included in the analysis (in addition, many
267 papers compiled patients' information so that information could not be pertaining to each
268 individual patient, which could not be included in the analysis). Gender, age, underlying disease,
269 and drug resistance of isolates were used to screen for factors that affect mortality to discover
270 influencing factors for mortality. The types of underlying diseases in dead and surviving patients
271 were similar. First, the χ^2 test was used to screen for single factors that may affect patient mortality
272 by category (shown in Table 3). Among the factors screened, kidney disease had a $P < 0.05$ and was
273 analyzed by multivariate analysis. As the number of factors with $P < 0.05$ was low, the inclusion
274 criteria were relaxed to $P < 0.1$ and tumor ($P = 0.076$) was included in multivariate analysis as a
275 suspected influencing factor (19,20).

276 Table 3: χ^2 test screening of single factors that may affect patient mortality by category

Influencing factor		Death toll	Number of survivors	P-value
Gender	Male	29	24	0.176
	Female	14	21	

Sepsis	Absent	38	41	0.727
	Present	11	10	
Fever	Absent	41	45	0.511
	Present	8	6	
Ear disease	Absent	49	50	0.325
	Present	0	1	
Diabetes	Absent	36	34	0.458
	Present	13	17	
Hypoglycemia	Absent	49	50	0.325
	Present	0	1	
Hypertension	Absent	43	41	0.315
	Present	6	10	
Hyperlipidemia	Absent	47	50	0.965
	Present	1	1	
Lung disease	Absent	33	38	0.43
	Present	16	13	
Tracheal disease	Absent	47	50	0.534
	Present	2	1	
Intestinal disease	Absent	42	46	0.491
	Present	7	5	
Brain disease	Absent	37	38	0.908
	Present	12	13	

Kidney disease	Absent	31	41	0.048
	Present	18	10	
Liver disease	Absent	46	49	0.614
	Present	3	2	
Gallbladder disease	Absent	48	50	0.977
	Present	1	1	
Tumor	Absent	34	43	0.076
	Present	15	8	
Chemotherapy	Absent	46	50	0.288
	Present	3	1	
Radiotherapy	Absent	48	51	0.305
	Present	1	0	
Nasopharyngeal disease	Absent	47	51	0.145
	Present	2	0	
Laryngeal disease	Absent	48	51	0.305
	Present	1	0	
Hematologic disease	Absent	43	46	0.697
	Present	6	5	
Heart disease	Absent	39	43	0.539
	Present	10	8	
Neuropathy	Absent	48	51	0.305
	Present	1	0	

Diseases of the ovary	Absent	49	50	0.325
	Present	0	1	
Vasculopathy	Absent	46	45	0.324
	Present	3	6	
Abnormal coagulation function	Absent	49	50	0.325
	Present	0	1	
Thyroid disorder	Absent	47	50	0.534
	Present	2	1	
Drug abuse	Absent	49	50	0.325
	Present	0	1	
Acquired immunodeficiency syndrome (AID)	Absent	47	49	0.967
	Present	2	2	
Bone marrow disease	Absent	47	49	0.967
	Present	2	2	
Oral disease	Absent	49	50	0.325
	Present	0	1	
Urinary tract disease	Absent	47	49	0.967
	Present	2	2	
Endometrial disease	Absent	49	50	0.325
	Present	0	1	
Cytomegalovirus (CMV)	Absent	48	51	0.305
	Present	1	0	

Psychiatric disorder	Absent	48	49	0.582
	Present	1	2	
Psoriasis	Absent	48	51	0.305
	Present	1	0	
Pressure ulcer	Absent	47	49	0.967
	Present	2	2	
Asthma	Absent	48	51	0.305
	Present	1	0	
Adrenal glands	Absent	49	50	0.325
	Present	0	1	
Prostate gland	Absent	48	51	0.305
	Present	1	0	
Breasts	Absent	49	50	0.325
	Present	0	1	
Bones	Absent	48	50	0.977
	Present	1	1	
Trauma	Absent	45	49	0.372
	Present	4	2	
Resistant	Sensitive	5	1	0.399
	1 type	5	6	
	2 types	8	10	
	3 type	5	6	

	5 types	1	0	
Age #		64 (45.50–73.35)	53.50 (39.75–72)	0.187

277 Note: # Non-normal distribution after normality test was carried out and expressed as median
 278 (interquartile range). P<0.1: Significant

279

280 Two suspected influencing factors (kidney disease and tumor) were selected based on the
 281 aforementioned univariate analysis and used for multivariate analysis. The outcome marker
 282 (mortality/survival) was used as a dependent variable and kidney disease and tumor were used as
 283 independent variables for logistic regression analysis (Table 4).

284 Table 4: Multivariate analysis results

	B	Standard error	Wald statistic	Degrees of freedom	Significance	OR	95%: confidence interval of OR	
							Lower limit	Upper limit
Kidney disease Present	-1.135	0.484	5.505	1	0.019	0.321	0.124	0.829
Kidney disease Absent	0					1		
Tumor Present	-1.156	0.519	4.962	1	0.026	0.315	0.114	0.870
Tumor Absent	0					1		
Constant	1.643	0.628	6.847	1	0.009	5.172		

285 Note: B: regression coefficient; OR: odds ratio.

286

287 The following conclusions were ultimately drawn from the multivariate analysis:

288 1. Kidney disease is an independent influencing factor for the outcome marker ($P=0.019<0.05$)
289 and the number of surviving patients with kidney disease was 32.1% of those without kidney
290 disease. 2. Tumor is an independent influencing factor for the outcome marker ($P=0.026<0.05$)
291 and the number of surviving patients with tumor is 31.5% of those without.

292 Based on the above conclusions, we selected kidney disease and tumor for prediction of
293 patient outcomes and the prediction accuracy rate was 65.7%. The accuracy rate was deemed
294 appropriate and the aforementioned conclusion had a good practical application value when the
295 prediction accuracy rate was $>60\%$ (33).

296

297 **Discussion**

298 *Candida auris* is an emerging pathogen and there is currently only a limited understanding of
299 the mechanisms and influencing factors that underpin associated infections. Hence, further studies
300 are required to help scientists better understand this pathogen. During the early stages of
301 emergence of a pathogen, information release along with medical and public health awareness are
302 extremely important.

303 In this analysis of collected literature, incomplete information was available for many
304 patients. The main reason for these gaps in information relate to the fact that *Candida auris*
305 isolates from these patients were not isolated during hospitalization but a few years later by public
306 health institutions and research institutions during retrospective screening of samples.
307 Furthermore, although *Candida auris* is difficult to culture many medical institutions still rely on
308 culture to identify microorganisms (34). In addition, *Candida auris* is closely related to *Candida*
309 *haemulonii* and *Candida pseudohaemulonii*. These three fungi are extremely close in phylogeny
310 and it is difficult to distinguish them by phenotype. Thus, traditional identification methods such

311 as Vitek 2 and API 20CAUX tend to wrongly identify *Candida auris* as these two closest
312 relatives.¹² Although the development of matrix-assisted laser desorption/ionization time-of-flight
313 mass spectrometry (MALDI-TOF MS) (35) and sequencing (36) strategies have helped in the
314 rapid and accurate diagnosis of *Candida auris*, most parts of the world do not have the
315 infrastructure to carry out these techniques. In addition, it is likely that there is a large volume of
316 unpublished data pertaining to *Candida auris* infections and the number of infected patients may
317 be far higher than that reported in the literature. Therefore, this is an “invisible pandemic”.

318 In this retrospective analysis, we found that the male to female ratio for patients was nearly
319 3:2 and mortality data revealed that the male to female ratio for mortality was close to 4:3. Similar
320 ratios have not been reported for other *Candida* infections (37). The proportion of *Candida auris*
321 patients with diabetes, kidney disease, and ear disease is higher than that reported for other
322 *Candida* infections. Diabetes is also a susceptibility factor for other candidiasis infections (20) but
323 the high infection rates observed for kidney disease and ear disease are specific for *Candida auris*.
324 Currently, almost all reported cases were from hospital wards. Jung et al. (21) reported that 78 out
325 of 79 *Candida auris* infection patients had a history of consultation with the otolaryngology
326 department; among these patients, 69 had ear disease and their symptoms were relatively mild.
327 Therefore, otolaryngology outpatient departments should be highly vigilant for *Candida auris*
328 infections. Among the *Candida auris* patient population, 21% had kidney disease; most of the
329 latter patients had chronic kidney disease or nephrotic syndrome. More importantly, kidney
330 disease is also an independent influencing factor that affects mortality in *Candida auris* infection
331 patients. Therefore, nephrologists should be extremely vigilant for *Candida auris* infection. As the
332 high infection rate in kidney disease patients is specific to *Candida auris* compared with other
333 *Candida* species, nephrologists in many regions do not have high awareness for *Candida auris*

334 infection. Many nephrologists do not completely understand *Candida auris*. Therefore, it is
335 important that *Candida auris*-related information be disseminated to various medical units,
336 particularly nephrology departments which can be extremely important in the early diagnosis of
337 *Candida auris* infections. In addition, many *Candida auris* patients exhibit severe symptoms and
338 although ICUs have been a focus of attention since *Candida auris* was first reported, overall
339 vigilance in ICUs is still not very strong and there is a need to strengthen knowledge gaps
340 pertaining to prevention, diagnosis, and treatment knowledge.

341 FLC exhibits broad-spectrum antifungal activity, good efficacy, a low incidence of adverse
342 reactions, and appropriate plasma concentrations for long durations (38). Therefore, this drug is
343 the most frequently utilized empirical therapy in patients suspected of fungal infection. *Candida*
344 *auris* has a high FLC resistance rate and the overall drug resistance ratio has been as high as 72%
345 over the last 10 years. Thus, FLC is not recommended as an empiric drug therapy when treatment
346 is urgent and drug sensitivity results have yet to be released for patients who either have been
347 infected with *Candida auris* or are suspected to have been infected with *Candida auris*. Clinicians
348 need to develop an awareness when considering whether FLC should be used as empiric therapy in
349 patients.

350 Although the data generated by this study reveal that there is no overall statistical correlation
351 between the degree of multidrug resistance in *Candida auris* and patient mortality, we did identify
352 some areas for attention after an in-depth analysis. Among the isolates for which patient mortality
353 could be determined, sensitive ones were isolated from 5 dead patients and the only sensitive
354 isolate was from only a surviving patient. We analyzed the possible reasons for the death of
355 information pertaining to isolates causing mortality and speculated that virulence and mortality
356 rates are higher when the *Candida auris* isolate is sensitive (39, 40). However, because sensitive

357 isolates can be treated with antibiotics, clinical outcomes can be changed if the patients are
358 diagnosed early and treated in a timely manner. Because candidiasis patients do not have apparent
359 clinical characteristics at an early stage, early laboratory tests are key to reducing the mortality rate
360 (11). Most Venezuelan and US patients exhibited VRC resistance. As these two countries are in the
361 Americas, this phenomenon suggests that there is a relationship between antifungal treatment
362 habits in different regions in the world.

363 In addition, among the acquired data, only one isolate that was resistant to 5 drugs was
364 obtained and this was isolated from a Malaysian patient where the outcome was death. Therefore,
365 when multidrug resistance in *Candida auris* gradually evolves, there will be situations where
366 patients cannot be treated by drugs and death will result. However, because the outcome for
367 patients infected with strains exhibiting only echinocandin resistance is death, vigilance is still
368 required for instances where the fungi isolated from patients do not show severe drug resistance
369 (e.g. resistance to 5 drugs). Echinocandin is currently the recommended treatment for *Candida*
370 *auris*. However, if *Candida auris* gradually evolves, more and more strains will develop
371 echinocandin resistance and this may lead to an increase in the mortality rate of patients with
372 *Candida auris* infections. Although the β -glucan synthesis inhibitor SCY-078 (41) and other new
373 drugs have shown some promise, they have not been widely used in clinical practice. Therefore, it
374 is especially important to develop new drugs to combat high levels of echinocandin resistance. The
375 appearance of antifungal drug resistance and the associated global range will continuously
376 threaten global public health (42) and cannot be ignored.

377 There are some limitations pertaining to this study. As this is a retrospective analysis of
378 published studies, there may be some original studies where the authors believed the associated
379 conditions were not important and some of the influencing factors were not mentioned. Thus, these

380 papers were not included in this current analysis. The stability of the drug sensitivity results from
381 different locations may vary. However, this study is the largest retrospective analysis of *Candida*
382 *auris* literature containing case data thus far. Additionally, as there was only a limited number of
383 patients with certain diseases, there might be a selection bias in this study.

384

385 **Conclusion**

386 This retrospective analysis provides us with a greater understanding of *Candida auris* along
387 with some of the main characteristics associated with *Candida auris*-infected patients. For
388 instance, the majority of the patients were male and had kidney disease or ear disease. It was also
389 observed that kidney disease can affect patient mortality in infected individuals. In addition, an
390 ever increasing number of multidrug resistant isolates have been identified and we should be
391 vigilant in relation to the evolution of drug resistance in *Candida auris*. Moreover, it is important
392 that we comprehensively improve diagnosis and treatment awareness for *Candida auris*.
393 Furthermore, we should actively develop early diagnostic techniques along with safe and effective
394 drugs for the treatment of *Candida auris* infections.

395

396 **Acknowledgements:**

397 This research was supported by Ministry of science and technology of the People's Republic of
398 China (2018ZX10101003 and 2018ZX10712-001), Jiangsu Provincial Medical Talent
399 (ZDRCA2016053), Six talent peaks project of Jiangsu Province (WSN-135)

400

401 **Conflict of interest:** The authors declare that they have no conflicts of interest.

402 **Research involving human participants and/or animals:** Not applicable.

403 **Informed consent:** Not applicable.


404 **References**

- 405 1. Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. 2009. *Candida*
406 *auris* sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an
407 inpatient in a Japanese hospital. *Microbiol Immunol* 53:41-44.
- 408 2. Fungal Diseases. Centers for Disease Control and Prevention. *Candida auris*. 5 May 2020.
409 <https://www.cdc.gov/fungal/candida-auris/index.html>.
- 410 3. The New York Times. 6 April 2019. A Mystery Infection, Spanning the Globe in a
411 Climate of Secrecy. <https://www.nytimes.com>.
- 412 4. Meis JF, Chowdhary A. 2018. *Candida auris*: a global fungal public health threat. *Lancet*
413 *Infect Dis* 18:1298-1299.
- 414 5. Rhodes J, Fisher MC. 2019. Global epidemiology of emerging *Candida auris*. *Curr Opin*
415 *Microbiol* 52:84-89.
- 416 6. Biswal M, Rudramurthy SM, Jain N, Shamanth AS, Sharma D, Jain K, Yaddanapudi LN,
417 Chakrabarti A. 2017. Controlling a possible outbreak of *Candida auris* infection: lessons
418 learnt from multiple interventions. *J Hosp Infect* 97:363-370.
- 419 7. Calvo B, Melo ASDA, Perozomena A, Hernandez M, Francisco EC, Hagen F, Meis JF,
420 Colombo AL. 2016. First report of *Candida auris* in America: Clinical and microbiological
421 aspects of 18 episodes of candidemia. *J Infect* 73:369-374.
- 422 8. Ku TSN, Walraven CJ, Lee SA. 2018. *Candida auris*: Disinfectants and Implications for
423 Infection Control. *Front Microbiol* 9.
- 424 9. Madder H, Moir I, Moroney R, Butcher L, Newnham R, Sunderland M, Clarke T, Foster D,
425 Hoffman P, Moore G. 2017. Multiuse patient monitoring equipment as a risk factor for
426 acquisition of *Candida auris*. [bioRxiv:149054](https://doi.org/10.1101/149054).
- 427 10. Cortegiani A, Misseri G, Giarratano A, Bassetti M, Eyre DW. 2019. The global challenge of
428 *Candida auris* in the intensive care unit. *Critical Care* 23:150.
- 429 11. Jefferysmith A, Taori SK, Schelenz S, Jeffery K, Johnson EM, Borman AM, Manuel R,
430 Brown CS. 2017. *Candida auris*: a Review of the Literature. *Clin Microbiol Rev* 31.
- 431 12. Shallu K, K. SP, Cheshta S, Anupam P, Aradhana M, Anil K, F. MJ, Anuradha C. 2015.

- 432 Multidrug-Resistant *Candida auris* Misidentified as *Candida haemulonii* : Characterization
433 by Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry and
434 DNA Sequencing and Its Antifungal Susceptibility Profile Variability by Vitek 2, CLSI
435 Broth Microdilution, and Etest Method. J Clin Microbiol 53.
- 436 13. Chowdhary A, Sharma C, Meis JF. 2017. *Candida auris*: A rapidly emerging cause of
437 hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog 13:1006290.
- 438 14. Chowdhary A, Voss A, Meis JF. 2016. Multidrug resistant *Candida auris*: New kid on the
439 block in hospital associated infections? J Hosp Infect:S0195670116303188.
- 440 15. Kim Hutchings Uke. 23 April 2018. *Candida auris* in healthcare settings – Europe.
441 [https://www.ecdc.europa.eu/sites/portal/files/documents/RRA-Candida-auris-European-U](https://www.ecdc.europa.eu/sites/portal/files/documents/RRA-Candida-auris-European-Union-countries.pdf)
442 [nion-countries.pdf](https://www.ecdc.europa.eu/sites/portal/files/documents/RRA-Candida-auris-European-Union-countries.pdf).
- 443 16. Rhodes J, Abdolrasouli A, Farrer RA, Cuomo CA, Aanensen DM, Armstrongjames D,
444 Fisher MC, Schelenz S. 2018. Genomic epidemiology of the UK outbreak of the emerging
445 human fungal pathogen *Candida auris*. Emerging microbes & infections 7:43.
- 446 17. Chow NA, De Groot T, Badali H, Abastabar M, Chiller T, Meis JF. 2019. Potential Fifth
447 Clade of *Candida auris*, Iran, 2018. Emerg Infect Dis 25:1780-1781.
- 448 18. Farina C, Manso E, Andreoni S, Conte M, Fazii P, Lombardi G, Sanna S, Russello G. 2011.
449 Interlaboratory evaluation of VITEK2 system and Sensititre YeastOne® for antifungal
450 susceptibility testing of yeasts isolated from blood cultures against four antifungal agents.
451 New Microbiol 34:195-201.
- 452 19. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. 2006. Variable
453 selection for propensity score models. Am J Epidemiol 163:1149-1156.
- 454 20. Jr DWH, Lemeshow S, Sturdivant RX. 2013. Applied Logistic Regression, 3rd Edition.
- 455 21. Mejiachew C, Ohalloran JA, Olsen MA, Stwalley D, Kronen R, Lin C, Salazar AS, Larson
456 L, Hsueh K, Powderly WG. 2019. Effect of infectious disease consultation on mortality
457 and treatment of patients with candida bloodstream infections: a retrospective, cohort study.
458 Lancet Infect Dis 19:1336-1344.
- 459 22. Oh BJ, Shin JH, Kim M, Sung H, Lee K, Joo MY, Shin MG, Suh S, Ryang DW. 2011.
460 Biofilm formation and genotyping of *Candida haemulonii*, *Candida pseudohaemulonii*,
461 and a proposed new species (*Candida auris*) isolates from Korea. Med Mycol 49:98-102.

- 462 23. Chowdhary A, Sharma C, Duggal S, Agarwal K, Prakash A, Singh PK, Jain S, Kathuria S,
463 Randhawa HS, Hagen F. 2013. New Clonal Strain of *Candida auris*, Delhi, India. Emerg
464 Infect Dis 19:1670-1673.
- 465 24. Magobo RE, Corcoran C, Seetharam S, Govender NP. 2014. *Candida auris*-associated
466 candidemia, South Africa. Emerg Infect Dis 20:1250-1251.
- 467 25. Emara M, Ahmad S, Khan Z, Joseph L, Alobaid I, Purohit P, Bafna R. 2015. *Candida auris*
468 Candidemia in Kuwait, 2014. Emerg Infect Dis 21:1091-1092.
- 469 26. Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP,
470 Colombo AL, Calvo B, Cuomo CA, Desjardins CA. 2017. Simultaneous Emergence of
471 Multidrug-Resistant *Candida auris* on 3 Continents Confirmed by Whole-Genome
472 Sequencing and Epidemiological Analyses. Clin Infect Dis 64:134-140.
- 473 27. Park JY, Bradley N, Brooks SE, Burney S, Wassner C. 2019. Management of Patients with
474 *Candida auris* Fungemia at Community Hospital, Brooklyn, New York, USA, 2016-2018.1.
475 Emerg Infect Dis 25:601-602.
- 476 28. Healey KR, Kordalewska M, Ortigosa CJ, Singh AK, Berrio I, Chowdhary A, Perlin DS.
477 2018. Limited ERG11 Mutations Identified in Isolates of *Candida auris* Directly
478 Contribute to Reduced Azole Susceptibility. Antimicrob Agents Chemother 62.
- 479 29. Rybak JM, Doorley LA, Nishimoto AT, Barker KS, Palmer GE, Rogers PD. 2019.
480 Abrogation of Triazole Resistance upon Deletion of CDR1 in a Clinical Isolate of *Candida*
481 *auris*. Antimicrob Agents Chemother 63.
- 482 30. Kordalewska M, Lee A, Park S, Berrio I, Chowdhary A, Zhao Y, Perlin DS. 2018.
483 Understanding Echinocandin Resistance in the Emerging Pathogen *Candida auris*.
484 Antimicrob Agents Chemother 62.
- 485 31. Hou X, Lee A, Jimenezortigosa C, Kordalewska M, Perlin DS, Zhao Y. 2018. Rapid
486 Detection of ERG11-Associated Azole Resistance and FKS-Associated Echinocandin
487 Resistance in *Candida auris*. Antimicrob Agents Chemother 63.
- 488 32. Chowdhary A, Prakash A, Sharma C, Kordalewska M, Kumar A, Sarma S, Tarai B, Singh
489 A, Upadhyaya G, Upadhyay SH. 2018. A multicentre study of antifungal susceptibility
490 patterns among 350 *Candida auris* isolates (2009–17) in India: role of the ERG11 and
491 FKS1 genes in azole and echinocandin resistance. J Antimicrob Chemother 73:891-899.
- 492 33. Palazonbru A, Tomasrodriguez MI, Lopezcascales MT, La Rosa DMF, Gilguillen VF. 2017.


- 493 Multivariate ordered logistic regression models: dealing with the model-building strategy. J
494 Pediatr Adolesc Gynecol 30:664.
- 495 34. Navalkele B, Revankar SG, Chandrasekar PH. 2017. *Candida auris*: a worrisome, globally
496 emerging pathogen. Expert Rev Anti Infect Ther 15:819-827.
- 497 35. Vatanshenassan M, Boekhout T, Meis JF, Berman J, Chowdhary A, Benami R, Sparbier K,
498 Kostrzewa M. 2019. *Candida auris* Identification and Rapid Antifungal Susceptibility
499 Testing Against Echinocandins by MALDI-TOF MS. Frontiers in Cellular and Infection
500 Microbiology 9:20.
- 501 36. Munoz JF, Gade L, Chow NA, Loparev VN, Juieng P, Berkow EL, Farrer RA, Litvintseva
502 AP, Cuomo CA. 2018. Genomic insights into multidrug-resistance, mating and virulence in
503 *Candida auris* and related emerging species. Nature Communications 9:5346.
- 504 37. Kohler JR, Hube B, Puccia R, Casadevall A, Perfect JR. 2017. Fungi that Infect Humans.
505 Microbiology spectrum 5:813-843.
- 506 38. Agrawal P B, Narang A, Kumar P. 1996. Fluconazole. Indian J Pediatr 63:775-780.
- 507 39. Lara HH, Ixtepanturrent L, Yacaman MJ, Lopezribot JL. 2020. Inhibition of *Candida auris*
508 Biofilm Formation on Medical and Environmental Surfaces by Silver Nanoparticles. ACS
509 Applied Materials & Interfaces.
- 510 40. Tan J, Liu Z, Sun Y, Yang L, Gao L. 2019. Inhibitory Effects of Photodynamic Inactivation
511 on Planktonic Cells and Biofilms of *Candida auris*. Mycopathologia 184:525-531.
- 512 41. Larkin EL, Hager C, Chandra J, Mukherjee PK, Retuerto M, Salem I, Long L, Isham N,
513 Kovanda LL, Borrotoesoda K. 2017. The Emerging Pathogen *Candida auris*: Growth
514 Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel
515 Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation. Antimicrob
516 Agents Chemother 61.
- 517 42. Fisher MC, Hawkins NJ, Sanglard D, Gurr SJ. 2018. Worldwide emergence of resistance to
518 antifungal drugs challenges human health and food security. Science 360:739-742.



World Bank, World Development Indicators (WDI), 2019. The copyright holder for this content is the International Bank for Reconstruction and Development / The World Bank. All rights reserved. No part of this content may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or by any information storage or retrieval system, without prior permission in writing from the copyright holder.


a

Gender




b

Age groups



a



b




Table 1. Underlying diseases in *Candida auris*-infected patients

Underlying disease	Number of people with disease	Proportion of patients
Diabetes	88	21%
Kidney disease	86	21%
Ear disease	74	18%
Trauma	63	15%
Lung disease	46	11%
Tumor	42	10%
Brain disease	41	10%
Sepsis	39	9%
Hypertension	37	9%
Heart disease	24	6%
Intestinal disease	18	4%
Liver disease	15	4%
Hematologic disease	12	3%
HIV	12	3%
Vasculopathy	10	2%
Thyroid disorder	7	2%
Diarrhea	7	2%
Pancreatic disease	4	1%
Bone marrow disease	4	1%
Urinary tract disease	4	1%
Pressure ulcer	4	1%
Nasopharyngeal disease	3	1%

Psychiatric disorder	3	1%
Other diseases	33	8%

Note: Other diseases are underlying disease categories with proportion of patients <0.5%.

Table 2: Risk factors involved in contact with *Candida auris* infected patients

Risk factor	Number of patients	Proportion of patients
ICU	254	65%
Broad-spectrum antibiotic treatment	232	60%
Central venous catheter	182	47%
Urinary catheter	141	36%
Underwent surgery in last 30 days	115	30%
Treatment with antifungal drugs in last 30 days before testing positive	104	27%
Mechanical ventilation	60	15%
Parenteral nutrition	40	10%
Steroid treatment	35	9%
Immunosuppressant	28	7%
Neutropenia	11	3%
Blood transfusion	4	1%

Table 3: χ^2 test screening of single factors that may affect patient mortality by category

Influencing factor		Death toll	Number of survivors	P-value
Gender	Male	29	24	0.176
	Female	14	21	
Sepsis	Absent	38	41	0.727
	Present	11	10	
Fever	Absent	41	45	0.511
	Present	8	6	
Ear disease	Absent	49	50	0.325
	Present	0	1	
Diabetes	Absent	36	34	0.458
	Present	13	17	
Hypoglycemia	Absent	49	50	0.325
	Present	0	1	
Hypertension	Absent	43	41	0.315
	Present	6	10	
Hyperlipidemia	Absent	47	50	0.965
	Present	1	1	
Lung disease	Absent	33	38	0.43
	Present	16	13	
Tracheal disease	Absent	47	50	0.534
	Present	2	1	

Intestinal disease	Absent	42	46	0.491
	Present	7	5	
Brain disease	Absent	37	38	0.908
	Present	12	13	
Kidney disease	Absent	31	41	0.048
	Present	18	10	
Liver disease	Absent	46	49	0.614
	Present	3	2	
Gallbladder disease	Absent	48	50	0.977
	Present	1	1	
Tumor	Absent	34	43	0.076
	Present	15	8	
Chemotherapy	Absent	46	50	0.288
	Present	3	1	
Radiotherapy	Absent	48	51	0.305
	Present	1	0	
Nasopharyngeal disease	Absent	47	51	0.145
	Present	2	0	
Laryngeal disease	Absent	48	51	0.305
	Present	1	0	
Hematologic disease	Absent	43	46	0.697
	Present	6	5	
Heart disease	Absent	39	43	0.539
	Present	10	8	

Neuropathy	Absent	48	51	0.305
	Present	1	0	
Diseases of the ovary	Absent	49	50	0.325
	Present	0	1	
Vasculopathy	Absent	46	45	0.324
	Present	3	6	
Abnormal coagulation function	Absent	49	50	0.325
	Present	0	1	
Thyroid disorder	Absent	47	50	0.534
	Present	2	1	
Drug abuse	Absent	49	50	0.325
	Present	0	1	
Acquired immunodeficiency syndrome (AID)	Absent	47	49	0.967
	Present	2	2	
Bone marrow disease	Absent	47	49	0.967
	Present	2	2	
Oral disease	Absent	49	50	0.325
	Present	0	1	
Urinary tract disease	Absent	47	49	0.967
	Present	2	2	
Endometrial disease	Absent	49	50	0.325
	Present	0	1	
Cytomegalovirus (CMV)	Absent	48	51	0.305
	Present	1	0	

Psychiatric disorder	Absent	48	49	0.582
	Present	1	2	
Psoriasis	Absent	48	51	0.305
	Present	1	0	
Pressure ulcer	Absent	47	49	0.967
	Present	2	2	
Asthma	Absent	48	51	0.305
	Present	1	0	
Adrenal glands	Absent	49	50	0.325
	Present	0	1	
Prostate gland	Absent	48	51	0.305
	Present	1	0	
Breasts	Absent	49	50	0.325
	Present	0	1	
Bones	Absent	48	50	0.977
	Present	1	1	
Trauma	Absent	45	49	0.372
	Present	4	2	
Resistant	Sensitive	5	1	0.399
	1 type	5	6	
	2 types	8	10	
	3 type	5	6	
	5 types	1	0	

Age #

64 (45.50–73.35) 53.50 (39.75–0.187

72)

Note: # Non-normal distribution after normality test was carried out and expressed as median (interquartile range). P<0.1: Significant

Table 4: Multivariate analysis results

		B	Standard error	Wald statistic	Degrees of freedom	Significance	OR	95%: confidence interval of OR	
								Lower limit	Upper limit
Kidney disease	Present	-1.135	0.484	5.505	1	0.019	0.321	0.124	0.829
	Absent	0					1		
Tumor	Present	-1.156	0.519	4.962	1	0.026	0.315	0.114	0.87
	Absent	0					1		
Constant		1.643	0.628	6.847	1	0.009	5.172		

Note: B: regression coefficient; OR: odds ratio.